Study S003345

A PHASE 1/2A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MET233 CO-ADMINISTERED WITH MET097 IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT INCLUDING PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS

ClinicalTrials.gov record

Registration

Registration: NCT06924320
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 381
Start: 2025-03-06
Primary completion: 2026-09-15
Lead sponsor: Pfizer
Conditions: Obesity and Obesity-related Medical Conditions
Interventions: DRUG:MET233 and MET097; OTHER:Placebo; DRUG:MET097
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:C6511001; OTHER:MET233/097-24-101

Registered primary outcomes

Occurrence of treatment-emergent adverse events (TEAEs) [Part A (Baseline, Day 85), Part B (Baseline, Day 155), Part C (Baseline, Day 155), Part D (Baseline, Day 218), Part E (Baseline, Day 246), Part G (Baseline, Day 274)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003887	Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Bailey CJ, Peptides	2026	Preclinical	PMID 41747885 DOI	cites ClinicalTrials.gov:NCT06924320; registry reference DERIVED:41747885